Abstract: New analysis tools are expanding the options for innovation researchers. While previous researchers often speculated on the relationship between inputs, such as patents or funding, and outcomes such as product releases or IPOs, new software tools enable researchers to analyze innovation event data more efficiently. Tools such as EventFlow make it possible to rapidly scan visual displays, algorithmically search for patterns, and study an aggregated view that shows common and rare patterns. This paper presents initial examples of how event analytic software tools such as EventFlow could be applied to innovation research, using data from 34,331 drugs or medical devices.
ecosystems. Understanding, modeling and measuring these dynamic and complex adaptive systems has become an important priority within science policy and scientometrics (Börner, 2016) .
Our modeling of research and development activities enriches the prevailing network approach with event analytics by focusing on time-stamped point events (such as getting a patent) or interval events (such as the funding period covered by a grant or contract).
We see STI processes as comprised of sequences of point and interval events that together result in the translation of knowledge and research into new products and services in the marketplace 1 .
Point events are associated with a single date / time, for example the date of a patent application.
Interval events are associated with start and end dates / times. Research projects or research grants with start and end dates are examples of interval events. These events generally fall into one of several categories including research, invention, proof, and several types of commercialization events 2 . Each event is associated with a document or record that describes the event, the key people and organizations involved and what roles they played, when and where the event occurred, along with other attributes. The information from these records, especially dates, may be used to model event networks of people, organizations, places and documents.
Events that contribute to the development of specific products and services may be associated with each other, creating product and service event sequences or trajectories. The trajectories may be connected through the networks of the people, organizations, places and documents 1 The phrases "products" or "products in the marketplace" are construed broadly throughout this paper to include all types of innovation and all types of "marketplaces" including public domain. 2 The order of activities here generally follows the linear model of innovation. This ordering is primarily a matter of convenience and should not be construed as proffering any particular model or theory of STI processes.
involved, and through their contributions to specific product and service event sequences.
Conceptually, this dual modeling structure (innovation networks / innovation event trajectories)
provides a linkage between STI as complex adaptive systems and STI as complex processes.
Why Innovation is Hard to Measure and how Event Analytics Can Help
A streamlined definition of innovation is the process of working on marketplace problems, which elicit innovators to transform ideas and scientific knowledge into new products (broadly defined to include services). The innovation process connects marketplace problems with research events, however each product follows a unique path involving different types of activities including research, publication, invention, prototyping, 'proof', and several commercialization events culminating in a new product launch. The trajectory a product takes may involve multiple events within any stage, and may involve revisiting a prior stage if remedial work is required.
Thus the first difficulty in measuring innovation is the unique and variable nature of the innovation trajectory or sequence of events for each product.
A second difficulty is that early stage research events are often undertaken for the purposes of knowledge creation and publication. In fact, the explicit innovation goal of a new product may not yet exist. There is a temptation to define the distinctions between science, technology and innovation more rigidly, but this creates as many problems as it solves. The creative moment when the product is first envisioned involves a specific set of conditions that are a function of the sequence and characteristics of events up to that point. It is as if the innovation path suddenly appears midway through the journey.
Mathematically this describes a Markov chain or Bayesian network model in which each event in the sequence is influenced by the cumulative effect of everything that has happened up to that point. Neither the final destination nor the intermediate events can be known with certainty.
They may however be estimated based on certain probability distributions.
Modeling and analyzing innovation event trajectories for successful products a posteriori establishes the basis for estimating those baseline probability distributions. This in turn allows the formulation and testing of more sophisticated hypotheses. It may also allow the development of predictive models, or facilitate machine learning and the development of related big data applications. Finally, the goal would be prescriptive modeling that would enable policy makers at funding agencies, investors, and entrepreneurs to make decisions that lead to more successful outcomes.
Current Innovation Metrics and the need for New Measures of Innovation
In 2011 the Committee on National Statistics and the Board on Science, Technology, and The emergence of tools for new data types offers fresh opportunities for innovation researchers to understand event patterns that could guide interventions to increase the success of innovation efforts. Current interest in event analytics has been triggered by the growth of electronic health records, which now provide online access to tens of millions of patient histories. These histories reveal patterns of medication compliance, links between treatments and side effects, and the relationship between interventions and outcomes (see for example Carter, Burd, Monroe, Plaisant and Shneiderman, 2013; Onukwugha, Plaisant, and Shneiderman, 2016) .
Increasing availability of innovation histories could produce similar benefits by allowing researchers for the first time to study the relationships between events in start-up companies and their eventual success or failure. Event analytics is a new and growing topic within visual analytics that combined interactive exploration with statistical tools to find expected common trajectories and unexpected anomalies. Patterns may be as simple as seeing how often patents lead to start-up companies getting founded or venture capital investments lead to acquisition of start-up companies, or they may be more complex.
Temporal event sequences consist of thousands or millions of events, which include the record ID (company name, ID#, etc.), a date-time-stamp (could be by the year or day or to the second, e.g. 2016-2-25), and an event category (patent, company launched, IPO, etc.) . This information about single point events can be assembled into records with a dozen or a thousand events.
( Table 1) [ Table 1 about here]
Temporal event sequences also include interval events, such as a one-year SBIR grant, a research project or clinical trial, in which case the event will have a start and an end date-time-stamp.
( Table 2 ).
[ Table 2 about here]
Initial efforts are usually to clean the data, which often contains incorrect, incomplete, redundant, mis-labeled, or surprising inputs. Typical errors include blank fields, erroneous record ID, misspelled event category, incorrect date-time-stamp, or a start date that is later than an end date.
Visual displays amplify human abilities to spot errors such as outliers in a scatterplot, surprising spikes in a timeline, or missing links in a network diagram.
The second data challenge involves record matching and disambiguation across data sources.
For example, this project involves matching data from FDA approvals, clinical trials, patents, research grants and other sources where EventFlow records correspond to individual products.
While products are named in the FDA databases and often in clinical trial data, those names often do not appear in patent or research grant data. Federal agencies including the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) have produces some adhoc databases that help with some of this matching -allowing us to present some preliminary results in this paper -but much of this work remains to be done.
Once data has been cleaned and matched, standard algorithms for identifying volatile or stable periods in time lines can be used to speed analyses. The combination of visual displays and statistical methods brings great power to analysts.
How Long Does Innovation Take?
Innovation trajectories 
Focusing on Drugs and Medical Devices
This paper demonstrates our analytic methods using drugs and medical devices, which is an important topic for which data is readily available because they are regulated products. We model innovation trajectories as sequences of events leading to the launch of a new products, which is the desired outcome for entrepreneurial success. Clinical trials and FDA approvals offer useful proxies for the commercialization process where available data is often limited.
Certain FDA approvals may also provide useful proxies for product launch dates.
Event Analytics for Innovation Trajectories
EventFlow There are more sophisticated questions that can be posed in event analytic tools, such as Do companies with three or more patents before product launches have more successful outcomes than companies with fewer patents?
Modeling and Measuring Innovation Trajectories: Data and Examples
The following examples are based on a dataset comprised of 34,331 records each representing a specific drug or medical device. Each record contains the events -research, patents, clinical trials and FDA approvals -associated with that product. In total the model includes 85,690
events. The list of event types and the count of each type is shown at the bottom of the left EventFlow panel shown in figure 2.
As a practical matter, answering the question how long does innovation take requires identifying start and end points. In our first example we take the date of first patent application as the starting point and a reasonable proxy for the date that the initial product idea was first conceived.
Limiting our analysis to drugs and medical devices, we take the date of final FDA approval as the end date and a reasonable proxy for product launch date. Neither the dates that commercial ideas were originally conceived, nor the actual product launch dates are reliably recorded or made publicly available, thus the need for proxies. Figures 3 and 4) . The visualizations suggest several additional research questions, demonstrating EventFlow's usefulness as a tool for data exploration.
The second example analyzes drug innovation trajectories from first patent to last FDA approval for 884 drugs resulting in mean, median and standard deviation metrics for these trajectories (see Figure 5 and 6).
Data gathering for Innovation Trajectories
We use the EventFlow software to model innovation trajectories in drugs and medical devices from multiple datasets:
[ Table 3 about here]
A Brief Introduction to EventFlow
Based on work with 40+ case study projects, we find that point and interval events provide [ Figure 5 about here] Figure 6 shows First Patent  FDA Approval for 688 drugs. The question of how long it takes to get a new drug to market is most often answered by rules of thumb or anecdotal evidence.
This image is among the first to actually show statistics and a distribution, with average duration of 9 years 4 months for two prevalent event sequence patterns. These results are preliminary.
Additional cleaning and matching of the data along with the augmentation of record attributes may allow for useful confidence intervals to be generated by, for example, segmenting the sample according to drug class or other attributes.
[ Figure 6 about here]
Discussion and Future Directions
This paper presents a new tool and novel approach for temporal analysis of innovation trajectories using examples and data from drug and medical device activities. While significant data processing work remains to match events from multiple datasets to product records, the brief examples shown in this paper suggest that temporal analysis of innovation trajectories with EventFlow can yield valuable information about the structure of innovation processes and new statistical metrics of how long these activities and processes take. and medical devices will allow exploration of questions regarding how differences in the sequences of activities impact innovation outcomes across a range of different technologies.
Other seemingly simple questions where the metrics developed using EventFlow could help include:
• Do innovation accelerators actually accelerate innovation? That is, do they shorten the duration of the innovation process from idea to market?
• Do regions with higher innovation network density innovate faster? What network structures are associated with faster innovation?
Both are active research questions for the authors. Regarding accelerators, a 2014 study of innovation accelerators for the U.S. Small Business Administration found no good metrics in the literature that answered the question of whether accelerators did indeed accelerate innovation (Dempwolf, Auer, and Dippolitto, 2014) . A subsequent network analysis comparing outcomes between 77 accelerator-affiliated startups and 77 non-accelerator-affiliated startups receiving angel funding using found that the accelerator subnetwork was 8.5 times larger than the unaffiliated angel network and exhibited more opportunity for brokerage. Accelerators invested 33% less per startup in angel funding ($100K vs $150K) and 50% less overall ($1.3B vs 2.6B) than unaffiliated angels. Combined their startups raised an additional $41B in subsequent funding rounds and acquisitions (Dempwolf, 2014) . While these results suggest that acceleratoraffiliated startups may be more efficient, they do not answer the question of whether the accelerator-related startups achieved those results faster than non-accelerator startups. A pending EventFlow offers the potential to answer that question using the same dataset 
Current Data Limitations
As promising as the preliminary results are, several data limitations are hindering broader application of this temporal analysis technology to understanding and measuring innovation processes.
1. Data is typically not collected or organized around products as the end result of innovation. Product data is available for drugs and medical devices because they are regulated and tested by product name. Otherwise, products are typically not identified in STI data sources. One data source that associates product names with the firms that produce them is the UPC database. The dates associated with UPC records are the date the record was last updated, not the date of product launch, however the source is worth further investigation.
2. STI data resides in multiple unlinked administrative databases and data quality is variable. Data cleaning, matching and disambiguation is a significant, time consuming and ongoing task. Records are not always complete and augmentation may be necessary. Efforts to automate data preparation processes through machine learning and other algorithms are underway but this will still take time.
3. Innovation processes are comprised of many different events and those events may involve different networks of people and organizations. Finding the relationships between events is not always easy. 
